Innovative Medicines Inspired By Patients With Renal Diseases

Averoa leverages considerable experience in drug development and registration to maximise product value and help innovative drugs reach their next step of development with a focus on renal diseases.

One in ten adults suffers from kidney disease

0 million
chronic Kidney disease patients
0 %
prevalence in Europe
0 + million
People die prematurely

Crucial Therapeutic Needs in Nephrology

With a patient-centered approach, our mission is to offer patients comprehensive care of their renal diseases, based on effective therapeutic options supported by accurate diagnosis and advanced prognosis tools.

The loss of kidney function is often progressive and asymptomatic in early stage. Our projects are specifically dedicated to proposing alternative treatments for patients suffering from renal diseases while also developing reliable biomarkers and tools to facilitate the diagnosis and assess treatment outcomes to improve the overall management of the patient.

Kidneys play a crucial role in maintaining homeostasis; their dysfunction affects virtually every part of the body. Management of patients with renal disease involves an interdisciplinary approach. There is a strong need to personalize treatment for patients.

An estimated 15% of the United States adult population and up to 13% of the European adult population have Chronic Kidney Diseases (CKD), a prevalence which is expected to grow with an aging population. 

Patients with CKD often suffer from other comorbidities, including cardiovascular disease, diabetes mellitus, and heart failure.

In addition to CKD, there are some 200 to 300 renal diseases for which mechanisms are unknown and often have a hereditary component.

Among these rare diseases, renal tubulopathies form a complex group of disorders which result in the inability of the tubule to exercise their functions. Disorders and their severity differ depending on the location within the tubule and the existence, or not, of compensatory pathways.

 submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of AVA1014 for Treating Complications Associated with Chronic Kidney Disease.